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ARTICLE
Bone protection by inhibition of microRNA-182
Kazuki Inoue1,2, Zhonghao Deng1, Yufan Chen3, Eugenia Giannopoulou1,4, Ren Xu 5, Shiaoching Gong6,
Matthew B. Greenblatt5, Lingegowda S. Mangala7,8, Gabriel Lopez-Berestein8,9, David G. Kirsch10,
Anil K. Sood7,8,11, Liang Zhao3 & Baohong Zhao 1,2,12
Targeting microRNAs recently shows signiﬁcant therapeutic promise; however, such pro-
gress is underdeveloped in treatment of skeletal diseases with osteolysis, such as osteo-
porosis and rheumatoid arthritis (RA). Here, we identiﬁed miR-182 as a key osteoclastogenic
regulator in bone homeostasis and diseases. Myeloid-speciﬁc deletion of miR-182 protects
mice against excessive osteoclastogenesis and bone resorption in disease models of
ovariectomy-induced osteoporosis and inﬂammatory arthritis. Pharmacological treatment of
these diseases with miR-182 inhibitors completely suppresses pathologic bone erosion.
Mechanistically, we identify protein kinase double-stranded RNA-dependent (PKR) as a new
and essential miR-182 target that is a novel inhibitor of osteoclastogenesis via regulation of
the endogenous interferon (IFN)-β-mediated autocrine feedback loop. The expression levels
of miR-182, PKR, and IFN-β are altered in RA and are signiﬁcantly correlated with the
osteoclastogenic capacity of RA monocytes. Our ﬁndings reveal a previously unrecognized
regulatory network mediated by miR-182-PKR-IFN-β axis in osteoclastogenesis, and highlight
the therapeutic implications of miR-182 inhibition in osteoprotection.
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Bone destruction is a major characteristic and severe con-sequence of multiple skeletal diseases, including osteo-porosis and inﬂammatory arthritis, and signiﬁcantly
reduces the quality of life of these patients and increases their risk
of disability. Osteoclasts are the sole specialized bone-resorbing
cells, which play an indispensable role as an exclusive pathogenic
factor in bone destruction associated diseases, such as rheumatoid
arthritis (RA) and postmenopausal osteoporosis1–6. MicroRNAs
(miRNAs) function as essential regulators of a variety of biolo-
gical and pathological settings, and have recently gained
increasing clinical attention as promising therapeutic targets or
biomarkers7–14. Functional studies of miRNAs have shown pro-
mise in preclinical development and several clinical trials in
cancer, metabolic and infectious diseases, highlighting miRNA-
based therapeutics toward a new era for disease treatment15–17.
Nonetheless, such progress in treatment of skeletal diseases has
not been made. Although the investigation of the role of miRNAs
in bone biology is expanding18–21, key miRNAs regulating
osteoclastogenesis and their functions in bone diseases still
remain underexplored.
miRNAs are evolutionarily conserved small noncoding RNAs
consisting of ~22 nucleotides that are spliced from longer pre-
cursor transcripts. miRNAs target speciﬁc mRNAs via imperfect
complementary binding but with a perfect base pairing between
the miRNA “seed region” (nucleotides 2–7 of the miRNA), and
the targeted sequences of mRNAs. miRNAs repress gene
expression at the posttranscriptional level by promoting degra-
dation and/or inhibiting translation of speciﬁc target mRNAs.
The expression and function of miRNAs are highly speciﬁc to cell
and tissue types and correlated with various stresses or disease
settings7,9–11,22,23. The functional diversity of each miRNA
appears to attribute to its targets and corresponding molecular
networks in different scenarios. Our initial exploration of miR-
NAs involved in osteoclastogenesis showed that miR-182 is a new
regulator in tumor necrosis factor (TNF)-induced inﬂammatory
osteoclast differentiation in vitro24. The important function of
miR-182 in cell growth, cell fate decision, cancer, and T lym-
phocyte expansion was just recently appreciated25–34. However,
the role of miR-182 in vivo in physiological bone metabolism and
pathological conditions such as that occur in osteoporosis and
inﬂammatory arthritis has not yet been elucidated.
In this study, we identify miR-182 as a key positive regulator of
osteoclastogenesis in both physiological and disease conditions
and provide new mechanisms for the regulation of osteoclasto-
genesis driven by the miR-182-PKR-IFN-β axis. Targeting miR-
182 and its downstream targets may represent an attractive
alternative or complementary therapeutic approach to prevent
pathologic bone destruction.
Results
miR-182 regulates osteoclastogenesis and bone homeostasis.
We ﬁrst examined the expression levels of miR-182 during
osteoclastogenesis using bone marrow-derived macrophages
(BMMs) as primary osteoclast precursors. In response to the
master osteoclastogenic inducer RANKL, miR-182 expression was
increased during a time course of osteoclast differentiation
(Fig. 1a). We next applied complementary genetic approaches
and generated osteoclastic miR-182 knockout and transgenic
mice. We deleted Mir182 speciﬁcally in myeloid lineage osteoclast
precursors by crossing Mir182ﬂox/ﬂox mice30 with LysMcre mice,
which express Cre under the control of the myeloid-speciﬁc
lysozyme M promoter, to generate Mir182ﬂox/ﬂoxLysMcre(+)
(hereafter referred to as Mir182ΔM/ΔM). Their littermates with a
Mir182+/+LysMcre(+) genotype (hereafter referred to as wild
type (WT)) are used as the controls. As a complementary genetic
approach, we generated myeloid lineage osteoclast precursor
conditional Mir182 transgenic (Mir182mTg) mice by crossing
LysMcre mice with LoxP-STOP-LoxP (LSL)–miR-182 mice30.
The littermate LysMcre mice were used as the Control. Compared
to the WT cell cultures, miR-182 deﬁciency in the Mir182ΔM/ΔM
BMM cultures strikingly inhibited TRAP-positive multinucleated
osteoclast formation induced by RANKL (Fig. 1b). Inhibition of
osteoclastogenesis by miR-182 deﬁciency was also observed in the
presence of RANKL with different concentrations (Supplemen-
tary Fig. 1). In parallel with suppressed generation of TRAP-
positive polykaryons, the expression of the key osteoclastogenic
transcription factors Nfatc1 (encoding NFATc1) and Prdm1
(encoding Blimp1) as well as osteoclast marker genes Acp5
(encoding TRAP), Ctsk (encoding cathepsin K) and Itgb3
(encoding β3 integrin) was dramatically decreased in RANKL-
treated Mir182ΔM/ΔM cells relative to the WT control cells
(Fig. 1c). Conversely, overexpression of miR-182 in BMMs
derived from Mir182mTg mice signiﬁcantly augmented the
osteoclastogenic program indicated by TRAP-positive osteoclast
differentiation and corresponding osteoclastic gene expression
compared with the control cell cultures (Supplementary
Fig. 2a–d). Human miR-182 was also induced by RANKL during
osteoclastogenesis using CD14-positive peripheral blood mono-
nuclear cells (PBMCs)-derived human osteoclast precursors
(Fig. 1d). Downregulation of miR-182 by a speciﬁc inhibitor in
human osteoclast precursors resulted in signiﬁcantly decreased
osteoclastogenesis (Fig. 1e) and the osteoclastic gene expressions
of NFATC1, PRDM1, CALCR (encoding calcitonin receptor),
and ITGB3 (Fig. 1f). These results indicate that miR-182 is an
important positive regulator promoting osteoclastogenesis. The
osteoclastogenic function of miR-182 is conserved in human cells.
We next analyzed the bone phenotype of the osteoclastic miR-
182 knockout and transgenic mice. Microcomputed tomographic
(μCT) analyses showed that Mir182ΔM/ΔM mice exhibited a
strong osteopetrotic phenotype indicated by markedly increased
bone mass (Fig. 1g, h), trabecular bone volume, bone mineral
density (BMD), connectivity density (Conn-Dens.), trabecular
bone number, and decreased trabecular bone spacing compared
to WT littermate control mice (Fig. 1h). The cortical bone
thickness was not altered by osteoclastic miR-182 deﬁciency
(Supplementary Fig. 3a). In contrast, Mir182mTg mice showed an
osteoporotic bone phenotype accompanied by decreased bone
mass (Supplementary Fig. 4a), trabecular bone volume, bone
mineral density, connectivity density, trabecular bone number,
and increased trabecular bone spacing compared to their
corresponding littermate controls (Supplementary Fig. 4b).
Furthermore, miR-182 affects osteoclast formation in vivo
evidenced by lower osteoclast numbers and smaller osteoclast
surface areas observed in the Mir182ΔM/ΔM mice than in the WT
controls (Fig. 1i, j). On the other hand, osteoclastic deﬁciency of
miR-182 does not affect bone formation rate, osteoblast numbers
and osteoblast surfaces (Supplementary Fig. 3b, c). Taken
together of the complementary bone phenotypes of osteoclastic
miR-182 knockout and transgenic mice as well as the impact of
miR-182 on osteoclastogenesis, these data demonstrate that miR-
182 is a key osteoclastogenic regulator and plays an essential role
in the maintenance of bone homeostasis.
miR-182 plays a crucial role in pathological bone loss. We next
turned to investigate the signiﬁcance of miR-182 in pathological
bone loss. With the consideration that the common bone diseases
associated with bone loss are osteoporosis and inﬂammatory
arthritis, we developed the ovariectomy (OVX) model in
Mir182ΔM/ΔM mice to study the role of miR-182 in estrogen
deﬁciency induced osteoporosis, which mimics postmenopausal
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bone loss, and an inﬂammatory arthritis model to study the role
of miR-182 in inﬂammatory bone resorption.
In the OVX-induced osteoporosis model, in order to assess the
success of the OVX, uterine weight was measured 5 weeks after
surgery. The uterine weight was decreased approximately 75% in
OVX groups compared with the sham groups (Fig. 2a), indicating
effective estrogen depletion. As expected in the WT mice, OVX
signiﬁcantly reduced bone mass indicated by almost 50% decrease
of BV/TV, BMD and Conn-Dens. and 25% decrease of trabecular
number, and about 30% increase of trabecular spacing compared
with the sham group (Fig. 2b, c columns 1 vs. 2) revealed by the
μCT analysis. Strikingly, the bone mass inMir182ΔM/ΔM mice was
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not decreased by OVX (Fig. 2b, c columns 3 vs. 4), indicating that
miR-182 deﬁciency completely protected Mir182ΔM/ΔM mice
against OVX-induced bone loss (Fig. 2b, c columns 3 vs. 4).
Notably, this protection is not attributed to the higher basal bone
volume in Mir182ΔM/ΔM mice than the WT mice, but because
miR-182 deﬁciency counteracts the bone loss induced by OVX in
Mir182ΔM/ΔM mice (Fig. 2b, c columns 3 vs. 4). Bone
histomorphometric analysis further showed signiﬁcantly larger
osteoclast numbers and surfaces in the WT OVX group than the
sham group (Fig. 2d, e columns 1 vs. 2). In contrast, OVX failed
to stimulate pathologic osteoclastogenesis in Mir182ΔM/ΔM mice
(Fig. 2d columns 3 vs. 4) and the osteoclastic parameters,
including osteoclast numbers and surfaces, remained comparable
between the sham and OVX of Mir182ΔM/ΔM mice (Fig. 2e
columns 3 vs. 4). Osteoclastic miR-182 deﬁciency did not affect
cortical thickness, bone formation rate, osteoblast numbers, and
osteoblast surfaces in the sham or OVX mice (Supplementary
Fig. 5a–c). These results indicate that osteoclastic deletion of miR-
182 appears to enable osteoclast lineage cells to become “tolerant”
to environmental osteoclastogenic stimuli, such as OVX, thereby
preventing pathologic bone loss.
In inﬂammatory settings, osteoclast precursors are generally
inﬂuenced by both RANKL and inﬂammatory cytokines, such
as TNF-α, which promotes osteoclast formation by priming
osteoclast precursors or acting in synergy with RANKL35–41.
We found that miR-182 deﬁciency dramatically repressed
osteoclast formation in the TNF-α or RANKL priming
conditions (Supplementary Fig. 6), suggesting a positive
regulatory role of miR-182 in osteoclastogenesis and bone
resorption under inﬂammatory conditions. To further test this
hypothesis in vivo, we ﬁrst used a well-established inﬂamma-
tory calvarial osteolysis mouse model induced by TNF-α or
lipopolysaccharides (LPS)42–46. Phosphate buffered saline
(PBS) injection as a negative control did not induce resorptive
pit formation on the calvarial bone surfaces (data not shown).
Administration of TNF-α to the Mir182mTg calvarial perios-
teum resulted in signiﬁcantly enhanced erosions, identiﬁable by
μCT analysis of the resorptive pits formed on the calvarial bone
surface (Fig. 2f, g), and markedly increased osteoclast formation
shown in the histological slices of the calvarial bones compared
to the control mice(Fig. 2h, i). In the LPS-induced inﬂamma-
tory bone resorption model, deletion of miR-182 in the
Mir182ΔM/ΔM mice almost completely inhibited LPS-induced
extensive bone destruction and osteoclast formation as
observed in the WT calvarial bones (Fig. 2j–m). Next, we
tested the role of miR-182 in a more pathologically relevant
model that mimics human diseases with characteristics of
inﬂammatory bone destruction. To do this, we chose K/BxN
serum-induced arthritis model47, which has been widely used to
study inﬂammatory peri-articular bone erosion induced by the
inﬂammatory cytokines in the serum. This model can bypass
the need to induce autoimmunity and thus allows investigation
of inﬂammatory bone resorption during the inﬂammatory
effector phase of arthritis. Deﬁciency of miR-182 in the
Mir182ΔM/ΔM mice resulted in striking suppression of peri-
articular bone erosion, osteoclast numbers and surfaces in
resorption sites (Fig. 2n, o) of the tarsal joints in the
inﬂammatory arthritis model when compared with the WT
control mice. The clinical course of inﬂammatory arthritis
indicated by the joint swelling was not diminished during the
10 day course except for bone erosion in Mir182ΔM/ΔM mice
(Supplementary Fig. 7), indicating that miR-182 does not
signiﬁcantly impact inﬂammation in this model but promi-
nently affects osteoclast formation and bone erosion.
Inhibition of miR-182 has therapeutic signiﬁcance. Our genetic
evidence inspired us to test the efﬁcacy of therapeutic targeting of
miR-182 to prevent bone loss for translational implications. To
provide a proof of concept experiment to test this hypothesis, we
chose nanoparticles as an effective and feasible in vivo delivery
method for an miR-182 inhibitor24, which has been validated to
speciﬁcally target miR-182. Chitosan (CH) has been extensively
used as drug delivery vehicles for small nucleotide oligos in
preclinical studies15,20,48–50. Prompted by the recent work using
CH-nanoparticles to effectively deliver small miRNAs in vivo to
successfully target osteoclasts20, we used the same optimized
packaging formula, in which the small RNA oligos have the
highest bio-distribution in bone marrow and target osteoclast
lineage efﬁciently20. In vivo injection of CH-nanoparticles did not
alter mouse body weight and bone mass (Supplementary
Fig. 8a–d), indicating the absence of obvious toxicity or effects on
bone from CH-nanoparticles per se.
In the OVX-induced osteoporosis model developed in the
C57BL/6 mice, successful OVX was ﬁrst validated by the uterine
atrophy in all OVX mice (Fig. 3a). Severe osteoporosis was
developed in the OVX mice injected with the CH-nanoparticles
containing the corresponding control RNA oligos 5 weeks after
surgery (Fig. 3b, c, columns 1 vs. 3). Strikingly, μCT analysis
revealed that treatment with CH-nanoparticles containing miR-
182 inhibitor oligos prevented the OVX-induced bone loss
(Fig. 3b, columns 3 vs. 4; 2 vs. 4), assessed by the bone mass
parameters BV/TV, BMD, Tb.N, Tb.Th, and Tb.Sp, to a similar
level relative to the sham groups (Fig. 3c, columns 3 vs. 4; 2 vs. 4).
In the sham groups, CH-nanoparticles containing miR-182
Fig. 1 miR-182 is a key positive regulator of osteoclastogenesis and bone homeostasis. aMature mouse miR-182 (mmu-mir-182) expression during RANKL-
induced osteoclastogenesis. b Osteoclast differentiation using BMMs derived from WT and Mir182ΔM/ΔM mice stimulated with RANKL for three days.
TRAP staining (left panel) was performed and the area of TRAP-positive MNCs (≥3 nuclei/cell) per well relative to the WT control was calculated (right
panel). TRAP-positive cells appear red in the photographs. c Quantitative real-time PCR analysis of mRNA expression of Nfatc1 (encoding NFATc1), Prdm1
(encoding Blimp1), Acp5 (encoding TRAP), Ctsk (encoding cathepsin K), and Itgb3 (encoding β3 integrin) during osteoclastogenesis using BMMs from the
WT and Mir182ΔM/ΔM mice treated with or without RANKL for 5 days. d Mature human miR-182 (hsa-mir-182) expression during RANKL-induced human
osteoclastogenesis using human CD14(+) PBMCs as osteoclast precursors. e Human osteoclast differentiation induced by RANKL for three days using
human CD14(+) monocytes that were transfected with the control or miR-182 Inhibitor. TRAP staining (left panel) was performed and the area of TRAP-
positive MNCs (≥3 nuclei/cell) per well relative to the Control was calculated (right panel). TRAP-positive cells appear red in the photographs.
f Quantitative real-time PCR analysis of mRNA expression of NFATc1, PRDM1, CALCR (encoding calcitonin receptor), and ITGB3 from 3 day-RANKL-
stimulated human CD14(+) monocytes transfected with the control or miR-182 inhibitor. g μCT images and h bone morphometric analysis of trabecular
bone of the distal femurs isolated from 10-week-old littermate male WT and Mir182ΔM/ΔM mice (n= 6/group). i TRAP staining and j histomorphometric
analysis of histological sections obtained from the metaphysis region of distal femurs of 10-week-old male WT and Mir182ΔM/ΔM mice. BV/TV, bone
volume per tissue volume; BMD, bone mineral density; Conn-Dens., connectivity density; Tb.N, trabecular number; Tb.Sp, trabecular separation; Oc.S/BS,
osteoclast surface per bone surface; N.Oc/B.Pm, number of osteoclasts per bone perimeter. b, c, e, f, h, j *p < 0.05; **p < 0.01 by Student’s t test. Error bars:
a–f Data are mean ± SD. h, j Data are mean ± SEM. Scale bars: b, e 200 µm; g 500 µm; i 100 µm
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inhibitors did not affect basal bone mass during the treatment
period (Fig. 3b, c, columns 1 vs. 2). Moreover, CH-nanoparticles
containing miR-182 inhibitors drastically suppressed OVX-
induced excessive osteoclast formation (Fig. 3d, e). The osteoclast
numbers and surfaces in the mice treated with CH-nanoparticles
containing miR-182 inhibitors were similar between the sham
and OVX groups (Fig. 3d, e). In addition, CH-nanoparticles
containing miR-182 inhibitors did not affect cortical thickness,
bone formation rate, osteoblast numbers and osteoblast surfaces
in the OVX model (Supplementary Fig. 9a–c). Thus, inhibition of
miR-182 implies an effective strategy in preventing bone loss
induced by estrogen deﬁciency.
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Compared with the CH-nanoparticles containing the control
RNA oligos, treatment of the mice with the CH-nanoparticles
containing miR-182 inhibitor oligos starting from the early stage
of inﬂammatory arthritis drastically suppressed osteoclast
formation indicated by nearly 70% decrease in osteoclast numbers
and 64% decrease in osteoclast surface areas, and as a
consequence effectively alleviated approximately 67% of inﬂam-
matory arthritic bone resorption (Fig. 3f, g). Similarly as
Mir182ΔM/ΔM mice, the CH-nanoparticles containing miR-182
inhibitor oligos did not prominently affect joint swelling
(Supplementary Fig. 10), indicating that miR-182 inhibition does
not signiﬁcantly suppress immune response in this arthritis
model. Thus, inhibition of miR-182 could serve as a promising
complementary approach to control excessive osteoclastogenesis
and bone loss in inﬂammatory settings while minimizing
undesired side effects on immune suppression.
Taken together of both of the genetic and pharmacological
evidence, miR-182 plays a prominent role in promoting
osteoclastic bone resorption in pathological conditions. Inhibition
of miR-182 reveals its therapeutic beneﬁts against pathologic
bone loss, such as that occurs in osteoporosis and inﬂammatory
arthritis.
miR-182 suppresses autocrine IFN-β pathway by targeting
PKR. We next sought to investigate the mechanisms by which
miR-182 functions as an osteoclastogenic regulator. To address
this question, we ﬁrst performed gene expression proﬁling using
high-throughput sequencing of RNAs (RNA-seq) with the WT
control and Mir182ΔM/ΔM osteoclast precursors at baseline and
after RANKL stimulation to identify genes regulated by miR-182
during osteoclastogenesis. In this study, two biological RNA-seq
replicates were performed for each condition followed by Pearson
correlation analysis to assess the reproducibility of RNA-seq data.
As shown in Supplementary Fig. 11, the gene expression values of
the two independent biological RNA-seq replicates are highly
correlated for each condition with Pearson’s R ≥ 0.986, indicating
a markedly high reproducibility between these replicates for each
condition. We then analyzed the RNA-seq data using these
replicates. RNA-seq-based expression heatmap of osteoclastic
genes regulated by miR-182 showed that the lack of miR-182
signiﬁcantly suppressed the expression of osteoclastogenic reg-
ulators, such as NFATc1 and Prdm1, and osteoclast marker
genes, such as TRAP, cathepsin K, OCSTAMP, DCSTAMP, and
Atp6v0d2 (Fig. 4a). These RNA-seq data are in alignment with
our ﬁndings on the suppressed osteoclastogenesis phenotype
resulted from miR-182 deﬁciency (Fig. 1). Gene Ontology (GO)
analysis of the upregulated genes by miR-182 deﬁciency during
RANKL-induced osteoclastogenesis revealed highly signiﬁcant
activation of genes involved in defense response, in particular
interferon-β response (p < 10−25, Fig. 4b). Gene set enrichment
analysis (GSEA) of the miR-182 regulated genes also revealed the
top signiﬁcant enrichment of type I interferons (IFN) response
genes (p < 0.0001 and FDR < 0.0001) in Mir182ΔM/ΔM cells in
response to RANKL (Fig. 4c). We further extracted the gene
expression values of the most enriched type I IFN response gene
set from our RNA-seq data and conﬁrmed 52 RANKL-regulated
IFN response genes that were highly enhanced in Mir182ΔM/ΔM
cells, such as MX1, IFIT2, IRF7, and CXCL10 (Fig. 4d). Previous
literature demonstrates that interferon pathway (IFN α, β, or γ)
inhibits osteoclast differentiation42,44,51,52. The endogenous IFN-
β induction by RANKL in osteoclasts is an important inhibitory
feedback loop to maintain a balanced differentiation state44,52.
Thus, the highly signiﬁcant enrichment of type I IFN response
gene sets in the Mir182ΔM/ΔM cells reﬂects a signiﬁcantly aug-
mented IFN pathway and could explain the phenotype of the
suppressed osteoclastogensis by miR-182 absence. It is of interest
how a miRNA controls such a speciﬁcally enriched group of
genes. It is unlikely that miR-182 directly targets all of these genes
because most of them do not contain miR-182 seed region. We
then hypothesized that miR-182 directly targets certain genes that
in turn speciﬁcally regulate IFN responsive genes during osteo-
clastogenesis. To this end, we performed two parallel RNA-seq
experiments, one with miR-182 loss of function approach using
the WT and Mir182ΔM/ΔM BMMs and the other with miR-182
gain of function approach using the control and Mir182mTg
BMMs, to ﬁrst identify genes regulated by miR-182 in osteoclast
precursors. We ﬁrst performed differential expression analysis
using edgeR and selected genes that were upregulated at least 1.2-
fold by the miR-182 deﬁciency and suppressed at least 1.2-fold by
the miR-182 overexpression with FDR < 0.05. With this com-
plementary approach we obtained a list of 24 genes, which con-
tained miR-182 potential targets. We then overlapped these genes
with a published database that has experimentally veriﬁed miR-
182 targets27, and determined four miR-182 direct targets
(Fig. 4e). In this group of genes, the gene Eif2ak2 encoding
protein kinase double-stranded RNA-dependent (PKR) stood out
with the highest expression level, whereas the other three genes
were only marginally expressed (Fig. 4e). Importantly, among
these four genes, only PKR is a well characterized factor that plays
a critical role in type I IFN pathway53–55, which indeed also ﬁt
our hypothesis that miR-182 targets PKR that further regulates
downstream IFN pathway. We further conﬁrmed the seed region
of miR-182 in the 3′ UTR of Eif2ak2 (Fig. 4f), and validated the
regulation of both mRNA and protein expression levels of PKR
by miR-182 using both Mir182ΔM/ΔM BMMs and Mir182mTg
BMMs (Fig. 4g, h). Furthermore, we performed a 3′ UTR
Fig. 2 miR-182 deﬁciency protects mice from pathologic bone loss induced by OVX or inﬂammatory arthritis. a–e 10-week-old female WT and Mir182ΔM/
ΔM mice were subjected to OVX or sham surgery and analyzed 5 weeks after surgery. a Uterine weight, b μCT images, and c bone morphometric analysis
of trabecular bone of the distal femurs isolated from the WT and Mir182ΔM/ΔM mice with sham or OVX surgery (n= 5/group). d TRAP staining and
e histomorphometric analysis of histological sections obtained from the metaphysis region of distal femurs isolated from the indicated mice. BV/TV, bone
volume per tissue volume; BMD, bone mineral density; Conn-Dens., connectivity density; Tb.N, trabecular number; Tb.Sp, trabecular separation; Oc.S/BS,
osteoclast surface per bone surface; N.Oc/B.Pm, number of osteoclasts per bone perimeter. f–i TNF-induced supracalvarial osteolysis model. f μCT images
of the surface of whole calvaria. g quantiﬁcation of the resorption area of the calvaria. h TRAP staining of calvarial histological sections and i
histomorphometric analysis of calvarial slices obtained from the Control and Mir182mTg mice after the application of TNF-α daily for ﬁve days to the
calvarial periosteum. n= 5 per group. j–m LPS-induced supracalvarial osteolysis model. j μCT images of the surface of whole calvaria, k quantiﬁcation of the
resorption area of the calvaria, l TRAP staining of calvarial histological sections, and m histomorphometric analysis of calvarial slices obtained from the WT
and Mir182ΔM/ΔM mice ﬁve days after the application of LPS to the calvarial periosteum. n= 5 per group. n TRAP staining of histological sections of tarsal
joints and o histomorphometric analysis of the tarsal joint sections obtained from the indicated mice that developed K/BxN serum-induced arthritis. ES/BS,
erosion surface per bone surface; Oc.S/BS, osteoclast surface per bone surface; N.Oc/B.Pm, number of osteoclasts per bone perimeter. a, c, e *p < 0.05;
**p < 0.01; n.s. not statistically signiﬁcant by two-way ANOVA. g, i, k, m, o **p < 0.01 by Student’s t test. Error bars: data are mean ± SEM. Scale bars: b 500
µm; d, h, l, n 200 µm; f, j 1.0 mm
ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/s41467-018-06446-0
6 NATURE COMMUNICATIONS |  (2018) 9:4108 | DOI: 10.1038/s41467-018-06446-0 | www.nature.com/naturecommunications
luciferase reporter assay, and found that miR-182 mimic down-
regulated the luciferase activity of the 3′ UTR of Eif2ak2 reporter
(Fig. 4i). Mutation of the seed region of miR-182 in the 3′ UTR of
Eif2ak2 abolished the regulatory effect of miR-182 on the 3′ UTR
of Eif2ak2 (Fig. 4f, i). These results collectively validate that PKR
is directly targeted by miR-182.
Following this line, we examined the role of PKR in osteoclast
differentiation, which has not been studied. The expression of
PKR was decreased along osteoclast differentiation (Fig. 5c,
Supplementary Fig. 12), indicating that PKR might be a negative
regulator in this process. To address this question, we utilized the
BMMs isolated from the PKR knockout (Pkr−/−) and WT control
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mice (Pkr+/+) as osteoclast precursors in three osteoclastic
culture systems activated by RANKL alone, RANKL or TNF
priming (Fig. 5a). In all conditions, PKR deﬁciency dramatically
increased osteoclast differentiation assessed by enhanced osteo-
clast generation and elevated gene expressions of osteoclastogenic
transcription factors, such as NFATc1 and Blimp1 (Fig. 5b, c,
Supplementary Fig. 12), as well as of osteoclast markers, such as
Ctsk and Dcstamp (Fig. 5b). These results indicate that PKR is a
novel inhibitor of osteoclastogenesis. Due to PKR’s involvement
in type I IFN pathway especially as an activator of IFN-β
expression53,54, we examined its expression and found that PKR
deﬁciency almost completely blocked the induction of IFN-β by
RANKL (Fig. 5d). As a consequence, the induction of IFN-β
response genes, such as Mx1, Iﬁt1, and Irf7, was strongly
suppressed in the PKR deﬁcient cell cultures induced by RANKL
relative to the control cell cultures (Fig. 5e). Next, we tested the
functional importance of the PKR-regulated IFN-β changes in
osteoclastogenesis. We blocked the inhibitory function of
endogenous IFN-β on osteoclastogenesis using an IFN-β
neutralizing antibody. Consistent with previous ﬁndings, blocking
of endogenous IFN-β enhanced RANKL-induced osteoclastogen-
esis in WT cell cultures (Fig. 5f). The effect of PKR deﬁciency on
the enhanced osteoclastogenesis, however, was abrogated by
blocking IFN-β, as evidenced by the data that PKR deletion
increased osteoclastogenesis in the presence of the control IgG,
but not in the presence of the IFN-β neutralizing antibody
(Fig. 5f). These results demonstrate that PKR is a new negative
regulator of osteoclastogenesis, which exerts inhibitory function
via induction of endogenous IFN-β expression. Finally, we
knocked down PKR expression in the Mir182ΔM/ΔM BMMs
(Fig. 5g), and found that the suppressed osteoclast differentiation
in Mir182ΔM/ΔM BMMs was signiﬁcantly reversed to a level
similar to that in the WT cells (Fig. 5h). These results indicate
that PKR is an essential downstream target responsible for the
miR-182 function in osteoclastogenesis. To further test whether
IFN-β is a critical downstream effector of miR-182, we examined
IFN-β expression and found that miR-182 deﬁciency signiﬁcantly
enhanced the RANKL-induced IFN-β levels (Fig. 6a). Impor-
tantly, the protein levels of IFN-β in the serum were also
markedly increased in the Mir182ΔM/ΔM mice (Fig. 6b). Further-
more, blocking of endogenous IFN-β using an IFN-β neutralizing
antibody (Fig. 6c) or by knocking down IFN-β expression
(Fig. 6d, e) abrogated the inhibitory effect of miR-182 deﬁciency
on the RANKL-induced osteoclastogenesis. Neutralization of
endogenous IFN-β did not have additional effect on the miR-182
overexpression-enhanced osteoclastogenesis in theMir182mTg cell
cultures (Fig. 6f). These ﬁndings indicate that IFN-β is a critical
downstream component of miR-182 during osteoclastogenesis.
Collectively, our data identify a previously unrecognized
mechanism (Fig. 6g) by which miR-182 directly targets PKR,
downregulation of which in turn suppresses endogenous IFN-β
expression induced by RANKL, thereby tuning down the
feedback inhibitory loop and activating osteoclastogenesis. This
newly identiﬁed miR-182-PKR-IFN-β pathway thus plays an
essential role in osteoclast differentiation and osteoclastogenic
gene expression program.
miR-182-PKR-IFN-β axis is signiﬁcantly correlated with RA.
Finally we set out to examine the expression levels of miR-182 in
the human osteoclast precursor CD14 (+) PBMCs isolated from
healthy donors and RA patients. As shown in Fig. 7a, human
miR-182 level was drastically elevated in RA patients. Given the
importance of TNF-α in the pathogenesis of RA and the
resounding success of TNF blockade therapy (TNFi) in the
treatment of RA, we next stimulated human CD14 (+) PBMCs
with TNF-α and found that TNF-α induced miR-182 expression
(Fig. 7b). TNF blockade therapy of RA patients with a humanized
antibody (Enbrel) that speciﬁcally blocks TNF activity strikingly
decreased miR-182 expression levels in CD14 (+) PBMCs after
one or two month-treatment (Fig. 7c left panel). In parallel, TNFi
signiﬁcantly decreased the osteoclastogenesis of RA PBMCs
(Fig. 7c right panel). Moreover, the therapeutic reduction of TNF
activity suppressed miR-182 expression as well as osteoclasto-
genesis in each individual RA patient after TNFi therapy (Fig. 7d).
Further statistical analysis revealed a strong correlation (Pearson’s
r= 0.748) between the levels of miR-182 expression and osteo-
clastogenesis in RA PBMCs (Fig. 7e). We next determined the
expression levels of PKR and IFN-β, the important downstream
factors of miR-182. In contrast to the higher level of miR-182 in
RA (Fig. 7a), both PKR and IFN-β levels were markedly lower in
RA PBMCs than in healthy donor cells (Fig. 7f). TNFi therapy
elevated the expression levels of PKR and IFN-β in RA PBMCs
(Fig. 7g). Signiﬁcant elevation of these two genes was also
determined in the monocytes isolated from each individual RA
patient after TNFi treatment (Fig. 7h). The osteoclastic levels of
PBMCs exhibited a strong negative correlation with the expres-
sion levels of PKR and IFN-β (Pearson’s r=−0.611 and −0.686,
respectively, in Fig. 7i). These results clearly show that the reg-
ulatory pattern of the miR-182-PKR-IFN-β axis is well conserved
in RA PBMCs. Upregulation of miR-182 accompanying with the
downregulation of PKR and IFN-β is strongly correlated with
osteoclastogenic levels in RA. The striking correlation between
the miR-182-PKR-IFN-β axis and osteoclastogenic potential of
RA PBMCs provides a piece of evidence that supports the
osteoclastogenic function of miR-182 in humans (Fig. 1e, f).
Taken together with the proof-of-concept therapeutic beneﬁts
obtained from animal models (Figs. 2, 3), these human data
highlight a promising therapeutic implication of targeting miR-
182 in suppressing excessive osteoclastogenesis and bone erosion
in human diseases.
Fig. 3 Pharmacological inhibition of miR-182 suppresses pathologic bone resorption in disease models. a–e OVX or sham operation was performed on 10-
week-old female C57BL/6 mice. Three days after surgery, the OVX and sham mice were treated with Control or miR182 inhibitor-carrying CH-
nanoparticles (n= 10 in the groups of Sham-control, Sham-miR-182 Inhibitor and OVX-control, and n= 9 in the group of OVX-miR-182 Inhibitor) at 5 μg
per mouse twice a week for 5 weeks. a Uterine weight, b μCT images, and c bone morphometric analysis of trabecular bone of the distal femurs isolated
from each group. d TRAP staining and e histomorphometric analysis of histological sections obtained from the metaphysis region of distal femurs isolated
from the indicated mice. n= 5 per group. f–g Inﬂammatory arthritis was induced by intraperitoneal injection of 100 µl of K/BxN serum to the mice on days
0 and 2. Control or miR182 inhibitor-carrying CH-nanoparticles were delivered by intravenous injections at 5 μg on day 2, 4, 6, and 8. Mice were sacriﬁced
on day 10. f TRAP staining and g histomorphometric analysis of histological sections of tarsal joints obtained from each group (n= 10 per group). BV/TV,
bone volume per tissue volume; BMD, bone mineral density; Tb.N, trabecular number; Tb.Th, trabecular thickness; Tb.Sp, trabecular separation; Oc.S/BS,
osteoclast surface per bone surface; N.Oc/B.Pm, number of osteoclasts per bone perimeter; ES/BS, erosion surface per bone surface. a, c, e *p < 0.05; **p <
0.01; n.s., not statistically signiﬁcant by two-way ANOVA. g **p < 0.01 by Student’s t test. Error bars: data are mean ± SEM. Scale bars: b 500 µm; d, f 200
µm
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Discussion
miRNAs exert functions through their speciﬁc targets and the
downstream pathways mediated by the targets. Identiﬁcation of
miRNA targets can reveal molecular mechanisms and regulatory
networks of each miRNA. By binding to complementary seed
region in target mRNAs, different miRNAs target different genes.
The target genes regulated by the same miRNA can also be
variable depending on cell and tissue types as well as various
stresses or disease settings7,9–11,22,23,30, presumably due to diverse
gene expression and regulation proﬁles in different conditions. In
this study, we identiﬁed eIF2ak2 (encoding PKR) as a new target
for miR-182 in response to RANKL during osteoclasogenesis.
Although other targets have been reported in different con-
texts25–34, PKR is an essential target of miR-182 in RANKL-
induced osteoclast differentiation evidenced by the data that
genetic deletion of PKR abolishes the function of miR-182 in
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osteoclastogenesis. PKR was initially discovered as an IFN-β
inducible gene in the antiviral response53–57. Double-stranded
RNA generated during viral replication activates PKR, which
functions as a kinase that phosphorylates the α-subunit of
eukaryotic translation initiation factor 2 (eIF2α) on Ser51.
Phosphorylation of eIF2α blocks translational initiation and
thereby promotes cellular apoptosis. PKR plays an important role
in type I IFN production. Recently, PKR has also been implicated
in regulating other cellular functions such as cell growth and
differentiation, gene transcription and translation, and signal
transduction. In addition to viruses, PKR can be activated
by other stimulations, such as TLRs, TNF, Insulin, and ER
stress58–61. The downstream signaling pathways activated by PKR
in these conditions are diverse, such as IFN-β, NF-κB signaling,
MAPK pathways and eIF2a-mediated translational inhibition,
dependent on cell types and context58–61. At the early stage of
osteoclast differentiation, PKR could presumably be regulated
directly by RANKL or indirectly by the autocrine IFN-β induced
by RANKL. The signiﬁcant downstream factor mediated by PKR
in osteoclastogenesis is IFN-β, which is supported by our data
that PKR deletion almost abrogates RANKL-induced expression
of IFN-β and the downstream type I IFN response genes. Along
differentiation, RANKL induces the expression of miR-182, which
in turn downregulates PKR expression, eventually shutting off
IFN-β expression and allowing osteoclastogenesis to proceed
efﬁciently. Few miRNAs were reported to act directly on PKR.
miR-182 thus is an miRNA newly identiﬁed to directly target
PKR, introducing miR-182 as an important regulator for IFN-β
signaling pathway.
Physiological osteoclast differentiation is delicately controlled
and maintained by complex mechanisms at various levels. The
extent of osteoclastogenesis is determined by the balance between
osteoclastogenic and anti-osteoclastogenic factors. Endogenous
IFN-β (even at very low levels) produced by macrophages/
osteoclast precursors in response to RANKL is a strong feedback
mechanism that inhibits osteoclast differentiation44,52. RANK
signaling needs to overcome the negative regulatory mechanisms,
such as by downregulating expression of transcriptional repres-
sors, to allow osteoclastogenesis to proceed52. Previously it was
unclear how the IFN-β mediated inhibitory loop was tuned down
during osteoclast differentiation. Our studies uncovered an
important mechanism that the miR-182-PKR axis is responsible
for suppressing autocrine IFN-β signaling. Kinetically, we
observed that miR-182 appears to be induced at a later time than
IFN-β during osteoclastogenesis. Thus, in order for osteoclasto-
genesis to proceed smoothly, RANKL induces a key positive
regulator miR-182 to speciﬁcally tune down a negative pathway
mediated by IFN-β that is activated at the early stage of differ-
entiation. These ﬁndings add a new regulatory circuit orche-
strated by miR-182 to the positive and negative regulatory
network of osteoclastogenesis (Fig. 6g). Overexpression of miR-
182 enables RANKL to induce efﬁcient osteoclast differentiation
at lower concentrations with approximately 25–50% of those used
in the control cell cultures (Supplementary Fig. 2d). On the other
hand, much higher concentrations of RANKL are required to
induce osteoclastogenesis in the miR-182 deﬁcient cells (Supple-
mentary Fig. 1). These results support the ﬁnding that miR-182
functions as a RANKL-inducible feed forward regulator to pro-
mote osteoclast differentiation. This regulatory mechanism is a
part of downstream signaling cascades of RANKL. Although the
strategies of direct blocking RANK receptor or neutralizing
RANKL are very effective in inhibition of osteoclastogenesis, they
could strongly or completely shut off osteoclastogenic program,
leading to potential long-term side effects, such as inhibition of
osteoclast-mediated bone remodeling. It is thus beneﬁcial to
develop complementary approaches to control abnormal osteo-
clastogenesis in disease conditions. Pathological scenarios, such as
inﬂammatory conditions in RA, can activate the miR-182-PKR
pathway in synergy with RANKL to promote osteoclast differ-
entiation. Therefore, appropriate regulation of miR-182-PKR axis
provides alternative possibilities to ﬁne tune osteoclastogenesis
instead of complete shutting off differentiation program in dis-
ease settings. Indeed, the data from our therapeutic models show
that the pharmacological inhibition of miR-182 suppresses
excessive osteoclasogenesis, but does not completely block the
differentiation and bone remodeling. Our ﬁndings provide new
insights into mechanisms that control the balance between
positive and negative pathways that determine the extent of
osteoclastogenesis and identify new therapeutic targets for inhi-
bition of pathologic bone resorption.
Despite a signiﬁcant progress in miRNA therapeutics, only a
small number of miRNA mimics or inhibitors have entered
clinical development15,16. One challenge is the design of miRNA
delivery approaches that can ideally make the miRNA-based
drugs stable and enable tissue-speciﬁc targeting, meanwhile
minimizing potential toxicities and off-target effects. Naked small
RNA molecules are easily degradable. Chemical modiﬁcation of
the nucleotide backbone of miRNA mimics or inhibitors, such as
modiﬁcation with locked nucleic acid (LNA), have improved their
binding afﬁnity and stability15. In our studies, the miR-182
inhibitor has LNA modiﬁcation. The initial preliminary results,
however, showed that a large amount of the miR-182 inhibitors
(~1 mg daily) was required to suppress osteoclastogenesis in vivo,
indicating a delivery vehicle is necessary to reduce amount.
Fig. 4miR-182 inhibits endogenous IFN-β signaling via targeting PKR. a–d RNA sequencing was performed using the mRNAs from the WT andMir182ΔM/ΔM
BMMs stimulated with or without RANKL for ﬁve days. n= 2 for each condition. #1, replicate 1. #2, replicate 2. a Heatmap of RANKL-induced osteoclast
marker genes and transcription factors regulated by miR-182 deﬁciency. Row z-scores of CPMs of osteoclast genes were shown in the heatmap. b Gene
ontology analysis of RANKL-inducible genes regulated by miR-182 deﬁciency. c Gene set enrichment analysis of RANKL-inducible genes regulated by miR-
182 deﬁciency ranked by NES. The enrichment plot of the hallmark of type I IFN response was shown on the right panel. d Heatmap of the enriched RANKL-
regulated type I interferon-response genes enhanced by miR-182 deﬁciency. #1, replicate 1. #2, replicate 2. e Left, Venn diagram showing the overlap of the
down-regulated genes in the Mir182mTg BMMs, upregulated genes in the Mir182ΔM/ΔM BMMs and the miR-182 targets obtained from a database27. RNA
sequencing data obtained from the mRNAs from theWT andMir182ΔM/ΔM BMMs, or the Control andMir182mTg BMMs were used. n= 2 for each condition.
Middle, a gene list extracted from the overlap of the three gene sets. Right, RPKM based gene expression of the four indicated genes. f Seed region of miR-
182 in the 3′ untranslated region of mouse Eif2ak2. g Quantitative real-time PCR (qPCR) analysis of mRNA expression of Eif2ak2 (encoding PKR) from WT
and Mir182ΔM/ΔM BMMs treated with or without RANKL for ﬁve days. Right, immunoblot analysis of PKR expression in WT and Mir182ΔM/ΔM BMMs.
h qPCR analysis of mRNA expression of Eif2ak2 from the Control and Mir182mTg BMMs treated with or without RANKL for two days. Right, immunoblot
analysis of PKR expression in the control and Mir182mTg BMMs. g, h Gapdh was used as a loading control. i Luciferase activities measured from the HEK293
cells co-transfected with the WT or mutant 3′ UTR of Eif2ak2 luciferase reporter plasmids together with miR-182 mimic or the corresponding control (n= 3).
Data are mean ± SD. **p < 0.01; n.s. not statistically signiﬁcant by two-way ANOVA
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Fig. 5 PKR as an essential target of miR-182 suppresses osteoclastogenesis by regulating IFN-β feedback. a Osteoclast differentiation determined by TRAP
staining (left panel) and the relative area of TRAP-positive MNCs per well (right panel) in the cell cultures using the Pkr+/+ and Pkr−/− BMMs that were
stimulated with RANKL for 3 days, or primed with TNF-α or RANKL for one day followed by costimulation with TNF-α and RANKL for 2 days. TRAP-positive
cells appear red in the photographs. b Quantitative real-time PCR analysis of mRNA expression of Nfatc1, Prdm1, Ctsk, and Dcstamp in BMMs from Pkr+/+
and Pkr−/− mice treated with or without RANKL for two days. c Immunoblot analysis of the expression of NFATc1, Blimp1, and PKR induced by RANKL at
the indicated times. p38 was used as a loading control. d, e Quantitative real-time PCR analysis of mRNA expression of Ifnb1 (d),Mx1, Iﬁt1, and Irf7 (e) in Pkr
+/+ and Pkr−/− BMMs treated with or without RANKL for two days. f BMMs from Pkr+/+ and Pkr−/− mice were treated with control IgG (10 U/ml) or
IFNβ-neutralizing Ab (10 U/ml) in the presence of RANKL for 3 days. Left panel: TRAP staining; Right panel: quantiﬁcation of the relative area of TRAP+
MNCs per well. g Quantitative real-time PCR analysis of mRNA expression of Eif2ak2 showing the knockdown efﬁciency of PKR in the WT and Mir182ΔM/
ΔM BMMs that were transfected with the control or Eif2ak2 speciﬁc LNAs (40 nM). h Osteoclast differentiation determined by TRAP staining (left panel)
and the relative area of TRAP-positive MNCs per well (right panel) in the WT and Mir182ΔM/ΔM BMM cell cultures transfected with the control or Eif2ak2
speciﬁc LNAs and stimulated with RANKL for 3 days. a, b, d, g **p < 0.01 by Student’s t test. f, h **p < 0.01; n.s. not statistically signiﬁcant by two-way
ANOVA. Error bars: data are mean ± SD. Scale bars: a, f, h 200 µm
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Indeed, recent in vivo delivery technologies, including nano-
particle systems, have enabled the ﬁrst generation of miRNA-
based agents to move into the preclinical development and clinic
trials15,16. CH is a cationic polymer derived from chitin and has
been extensively used for small RNA delivery in preclinical stu-
dies due to its biodegradability and low cellular toxicity. We
applied CH-nanoparticles to incorporate miR-182 inhibitors and
reduced approximately 600 times of the amount of miR-182
inhibitors to 5 µg every 3 days to suppress osteoclastogenesis, and
this small amount of miR-182 inhibitors showed efﬁcient sup-
pression of miR-182 expression in bone marrow (Supplementary
Fig. 8e). The low amount of miR-182 inhibitors using CH delivery
system not only functions efﬁciently but also could lower off-
targeting effect and cellular toxicity. CH is FDA-approved safe for
wound dressing and dietary use, and there are several animal
toxicity studies, including our results, reporting good safety
in vivo62. Nonetheless, future studies in preclinical and clinical
development need further optimization of the delivery system to
eventually achieve a successful clinical application. The nano-
particle formula decides the particle size and weight that usually
delicately determine the speciﬁcity of targeting certain cells49,50.
For example, the CH formula used in this study facilitates tar-
geting monocytes/macrophages and bone marrow. While our
data from in vitro and in vivo experiments illustrate the
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time PCR analysis of mRNA expression of Ifnb1 showing the knockdown efﬁciency of Ifnb1 in the WT and Mir182ΔM/ΔM BMMs that were transfected with
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hsa-mir-182 expression in CD14(+) PBMCs isolated from healthy donors and RA patients. n= 10/group. b qPCR analysis of hsa-mir-182 expression in
human CD14(+) PBMC-derived macrophages treated with TNF-α (40 ng/ml). c Left, qPCR analysis of hsa-mir-182 expression in CD14(+) PBMCs from RA
patients before (basal) and after TNFi (Enbrel) for 1 and 2 months. Right, osteoclast differentiation indicated by the relative area of TRAP-positive MNCs in
the cell cultures of human CD14(+) PBMC-derived macrophages treated with RANKL (100 ng/ml) for 5 days. Relative area of TRAP-positive MNCs was
determined per well. n= 10/group. d Left, qPCR analysis of the relative expression of hsa-mir-182 in CD14(+) PBMCs from the same RA patient before and
after TNFi (Enbrel) for 1 and 2 months. Right, relative area of TRAP-positive MNCs. Results in each panel were normalized to the basal condition for each
patient. n= 10/group. e Scatter plot showing signiﬁcant positive correlation between the relative TRAP-positive osteoclast area and hsa-mir-182
expression. Each dot represents an RA patient in the indicated conditions. Pearson’s r= 0.748. f qPCR analysis of mRNA expression of EIF2AK2 (encoding
PKR) or IFNB1 (encoding IFN-β) in CD14(+) PBMCs from healthy donors and RA patients. n= 10/group. g qPCR analysis of mRNA expression of EIF2AK2
or IFNB1 in CD14(+) PBMCs from RA patients before and after TNFi (Enbrel) for 1 and 2 months. n= 10/group. h Relative expression of EIF2AK2 or IFNB1 in
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represents an RA patient. Pearson’s r=−0.611 (left) or −0.686 (right). a, f **p < 0.01 by Student’s t test; c, d, g, h **p < 0.01; n.s. not statistically signiﬁcant
by repeated measures ANOVA; data are mean ± SEM
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inhibition of osteoclastogenesis and bone resorption by the miR-
182 inhibitor, we are aware of the possibility that the miRNA
inhibitor-containing nanoparticles might also target additional
cells in vivo. Therefore, further analyses of other potential cellular
targets of this miRNA inhibitor during long-term treatment
in vivo as well as development of more osteoclast-speciﬁc tar-
geting delivery approaches should be conducted when developing
clinical therapeutic applications.
Our results show that miR-182 functions as a key osteoclas-
togenic factor in human osteoclastogenesis as well. The regulatory
pattern of the expression changes of the miR-182-PKR-IFN-β
axis along with osteoclastogenesis in mice is similarly determined
in human cells, indicating that the miR-182-mediated mechan-
isms are likely to translate to human physiopathology. The
positive correlation between miR-182 expression levels and the
osteoclastogenic extent in humans also suggests a possibility of
miR-182 as a clinical biomarker of osteoclastogenesis, which will
require validation by large-scale cohort studies. Taken together of
the genetic evidence from both in vitro and in vivo systems,
strong correlation between miR-182 expression levels and
osteoclastogenic potential in RA, and the in vivo pharmacological
results obtained from animal disease models, our study provides a
proof of concept for the efﬁcacy of therapeutic targeting of miR-
182 to prevent bone loss and highlights the translational impli-
cations of targeting miR-182 and its downstream targets in
treating osteolytic diseases.
Methods
Animal study and analysis of bone phenotype. We generated mice with
myeloid-speciﬁc deletion of miR-182 by crossing Mir182ﬂox/ﬂox mice30 with mice
with a lysozyme M promoter-driven Cre transgene on the C57BL/6 background
(known as LysMcre; The Jackson Laboratory). Gender- and age-matched
Mir182ﬂox/ﬂoxLysMcre(+) mice (referred to as Mir182ΔM/ΔM) and their littermates
with Mir182+/+LysMcre(+) genotype as WT controls were used for experiments.
Myeloid-speciﬁc miR-182 overexpression mice (referred to as Mir182mTg) were
generated by crossing LSL(LoxP-Stop-LoxP)–Mir182 mice30, in which the mouse
Mir182 cDNA was knocked into the ubiquitously expressed Rosa26 locus preceded
by a STOP fragment ﬂanked by loxP sites, and Cre activates miR-182 over-
expression, with LysMcre on the C57BL/6 background (The Jackson Laboratory).
Gender- and age-matched Mir182mTg mice and their littermates LysMcre mice as
controls (referred to as Control) were used. Eif2ak2 (encoding Pkr) knockout mice
(referred to as Pkr−/−) were described previously63. The bone marrow isolated
from gender- and age-matched Pkr−/− and WT Pkr+/+ were used in the experi-
ments. All animal procedures were approved by the Hospital for Special Surgery
Institutional Animal Care and Use Committee (IACUC), and Weill Cornell
Medical College IACUC.
Bilateral OVX or sham operation (Sham) was performed on 10-week-old female
mice. The mice were sacriﬁced 5 weeks after surgery, uterine atrophy was ﬁrst
conﬁrmed and then bones were collected for µCT and histological analysis.
For inﬂammatory osteolysis experiments, we used the established LPS-induced
or TNF-induced supracalvarial osteolysis mouse model42–46 with minor
modiﬁcations. LPS was administrated at the dose of 12.5 mg/kg weight to the
calvarial periosteum of age and gender-matched mice. Five days after LPS injection,
the mice were sacriﬁced and the calvarial bones and serum were collected. For
TNF-induced supracalvarial osteolysis model, TNF-α was administrated daily at
the dose of 75 µg/kg to the calvarial periosteum of age and gender-matched mice
for ﬁve consecutive days before the mice were sacriﬁced. The calvarial bones were
subjected to µCT analysis, sectioning, TRAP staining, and histological analysis.
For Inﬂammatory arthritis experiments, we used K/BxN Serum Transfer-
Induced Arthritis model47. K/BxN serum pools were prepared, and arthritis was
induced by intraperitoneal injection of 100 µl of K/BxN serum to the female mice
on days 0 and 2. The development of arthritis was monitored by measuring the
thickness of wrist and ankle joints with digital slide caliper (Bel-Art Products). For
each animal, joint thickness was calculated as the sum of the measurements of both
wrists and both ankles. Joint thickness was represented as the average for each
group. Mice were sacriﬁced on day 10 and serum and paws were collected. Hind
paws were subjected to sectioning, TRAP staining, and histological analysis.
For in vivo miR-182 inhibitor delivery, we used CH-nanoparticles as a delivery
vehicle20. The control or miR-182 inhibitor-carrying CH-nanoparticles were
delivered by intravenous injections at 5 µg (in 100 µl PBS) per mouse, with twice a
week for 5 weeks starting from 3 days after surgery for OVX models or on day 2, 4,
6, 8 for arthritis models. µCT analysis was conducted to evaluate bone volume and
3D bone architecture using a Scanco µCT-35 scanner (SCANCOMedical). Mice
femora were ﬁxed in 10% buffered formalin and scanned at 6 µm resolution.
Proximal femoral trabecular bone parameters or the cortical bone parameters
obtained from the midshaft of femurs were analyzed using Scanco software
according to the manufacturer’s instructions and the American Society of Bone and
Mineral Research (ASBMR) guidelines43,64. Femur and calvarial bones were
subjected to sectioning, TRAP staining and histological analysis. For dynamic
histomorphometric measures of bone formation, calcein (25 mg/kg, Sigma) was
injected into mice intraperitoneally at 4 and 1 days before sacriﬁce to obtain double
labeling of newly formed bones. The non-decalciﬁed tibiae bones were embedded
in methyl methacrylate. Sections measuring 5-μm thick were cut on a microtome
(Leica RM2255, Leica Microsystems, Germany). For static histomorphometric
measures of osteoblast parameters, undecalciﬁed sections of the tibiae were stained
using Masson-Goldner staining kit (MilliporeSigma). The osteomeasure software
was used for bone histomorphometry using standard procedures according to the
program’s instruction.
General experimental design. Generally, sample sizes were calculated on the
assumption that a 20–30% difference in the parameters measured would be con-
sidered biologically signiﬁcant with an estimate of sigma of 10–20% of the expected
mean (α set at 0.05). For each in vivo experiment, at least ﬁve mice per genotype or
per treatment condition were used. No animals were excluded from the analysis.
Experimental animals were grouped according to their genotypes. Within the same
genotype group in each experiment, the mice were randomized to different pro-
cedures, such as Sham vs. OVX, or to different treatments, such as PBS vs. cytokine
treatment, control nanoparticles vs. miR-182 inhibitor nanoparticles. Investigators
performing μCT or histomorphometry analysis were blinded to the genotype and
treatment group of each sample.
Reagents. Murine or human M-CSF, murine or human TNF-α, and soluble
human RANKL were purchased from PeproTech. In vivo mouse miR-182 inhibitor
and its in vivo corresponding control, Eif2ak2 LNA, Ifnb1 LNA, and negative-
control LNA were purchased from Exiqon. Human miR-182 inhibitor and its
control were purchased from Ambion. mirVana™ miRNA miR-182 mimic and its
corresponding negative control (Cat # 4464058) were purchased from Life Tech-
nologies. Mouse rIFN-β was obtained from PBL Technology. IFN-β-neutralizing
antibody (rabbit polyclonal antibody against mouse IFN-β) was from PBL Tech-
nology and the control IgG (rabbit) was obtained from Santa Cruz Biotechnology.
The miR-182 inhibitor (5′-TTCTACCATTGCCAA-3′) or the corresponding
control (5′-ACGTCTATACGCCCA-3′) (HPLC puriﬁed, Exiqon) was packaged
into CH-nanoparticles20. The miR-182 inhibitor and its control obtained from
Exiqon have fully phosphorothioate (PS)-modiﬁed backbones, which enhances
stability, pharmacokinetic and pharmacodynamic properties in vivo (http://ipaper.
ipapercms.dk/EXIQON/Marketing/guidelines/analyzing-rna-function-in-animal-
models/).
Cell culture. To obtain BMMs, mouse bone marrow cells were harvested from
tibiae and femora of age and gender-matched mutant and control mice and cul-
tured for 3 days in α-MEM medium (Thermo Fisher Scientiﬁc) with 10% fetal
bovine serum (FBS) (Atlanta Biologicals), glutamine (2.4 mM, Thermo Fisher
Scientiﬁc), Penicillin–Streptomycin (Thermo Fisher Scientiﬁc) and
CMG14–12 supernatant (condition medium, CM), which contained the equivalent
of 20 ng/ml of rM-CSF and was used as a source of M-CSF43. The attached BMMs
were scraped, seeded at a density of 4.5 × 104/cm2, and cultured in α-MEM
medium with 10% FBS, 1% glutamine and CM for overnight. Except where stated,
the cells were then treated without or with optimized concentrations of RANKL
(40 ng/ml) or TNF-α (40 ng/ml) in the presence of CM for times indicated in the
ﬁgure legends. Culture media were exchanged every three days. For human
osteoclast cultures, PBMCs from whole blood of healthy volunteers or RA patients
were isolated by density gradient centrifugation using Ficoll (Invitrogen Life
Technologies, Carlsbad, CA). CD14(+) cells were puriﬁed from fresh PBMCs using
anti-CD14 magnetic beads (Miltenyi Biotec, Auburn, CA) as recommended by the
manufacturer. Human CD14(+) monocytes were cultured in α-MEM medium
with 10% FBS in the presence of M-CSF (20 ng/ml; PeproTech, Rocky Hill, NJ) for
2 days to obtain monocyte-derived macrophages, which were further cultured with
RANKL for osteoclast differentiation. The RA CD14(+) PBMCs were from RA
patients (age ≥18 and <70 years) who fulﬁlled American College of Rheumatology
(ACR) 2010 RA classiﬁcation criteria with disease duration <5 years and were
under TNFi therapy for the ﬁrst time (Enbrel, 25 mg weekly). Experiments with
human cells were approved by Nanfang Hospital (China) and the Hospital for
Special Surgery (USA) Institutional Review Board. Informed consent (PBMC
collection) was obtained from all RA patients. TRAP staining was performed with
an acid phosphatase leukocyte diagnostic kit (Sigma-Aldrich) in accordance with
the manufacturer’s instructions. Human embryonic kidney 293 cells were pur-
chased from the American Type Culture Collection. HEK293 cells were grown in
Dulbecco’s modiﬁed Eagle’s media with 10% FBS. The cell line was routinely tested
for mycoplasma contamination.
In vitro inhibition of miRNAs and gene silencing. miRNA inhibitors speciﬁcally
targeting hsa-mir-182 or non-targeting control oligos (Ambion) were transfected
into primary human CD14(+) monocytes at concentrations of 40 nM with the
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Amaxa Nucleofector device set to program Y-001 using the Human Monocyte
Nucleofector kit (Lonza). Antisense inhibition using locked nucleic acid (LNA)
technology from Exiqon was applied to silence gene expression in vitro. LNA
oligonucleotides speciﬁcally targeting Eif2ak2 and non-targeting control LNAs
were from Exiqon and were transfected into murine BMMs at concentrations of 40
nM using TransIT-TKO transfection reagent (Mirus) in accordance with the
manufacturer’s instructions.
Reverse transcription and real-time PCR. DNA-free RNA was obtained with the
RNeasy MiniKit (Qiagen, Valencia, CA) with DNase treatment, and 1 µg of total
RNA was reverse-transcribed with random hexamers and MMLV-Reverse Tran-
scriptase (Thermo Fisher Scientiﬁc) according to the manufacturer’s instructions.
Real-time PCR was done in triplicate with the QuantStudio 5 Real-time PCR
system and Fast SYBR® Green Master Mix (Thermo Fisher Scientiﬁc) with 500 nM
primers. mRNA amounts were normalized relative to glyceraldehyde-3-phosphate
dehydrogenase (GAPDH) mRNA. When RT was omitted, threshold cycle number
increased by at least ten, signifying lack of genomic DNA contamination or
nonspeciﬁc ampliﬁcation; the generation of only the correct size ampliﬁcation
products was conﬁrmed with agarose gel electrophoresis. The primers for real-time
PCR were as follows: Nfatc1: 5′-CCCGTCACATTCTGGTCCAT-3′ and 5′-CAAG
TAACCGTGTAGCTCCACAA-3′; Prdm1: 5′-TTCTTGTGTGGTATTGTCGGG
ACTT-3′ and 5′-TTGGGGACACTCTTTGGGTAGAGTT-3′; Acp5: 5′-ACGGC
TACTTGCGGTTTC-3′ and 5′-TCCTTGGGAGGCTGGTC-3′; Ctsk: 5′-AAGAT
ATTGGTGGCTTTGG-3′ and 5′-ATCGCTGCGTCCCTCT-3′; Itgb3: 5′-CCGG
GGGACTTAATGAGACCACTT-3′ and 5′-ACGCCCCAAATCCCACCCATA
CA-3′; Dc-stamp: 5′-TTTGCCGCTGTGGACTATCTGC-3′ and 5′-AGACGTGG
TTTAGGAATGCAGCTC-3′; Pkr: 5′-AACCCGGTGCCTCTTTATTC-3′ and 5′-
ACTCCGGTCACGATTTGTTC-3′; Ifnb1: 5′-TTACACTGCCTTTGCCATCC-3′
and 5′-AGAAACACTGTCTGCTGGTG-3′; Mx1: 5′-GGCAGACACCACATAC
AACC-3′ and 5′- CCTCAGGCTAGATGGCAAG-3′; Iﬁt1: 5′-CTCCACTTTCAG
AGCCTTCG-3′ and 5′-TGCTGAGATGGACTGTGAGG-3′; Irf7: 5′-GTCTCGG
CTTGTGCTTGTCT-3′ and 5′-CCAGGTCCATGAGGAAGTGT-3′; and Gapdh:
5′-ATCAAGAAGGTGGTGAAGCA-3′and 5′-AGACAACCTGGTCCTCAGTGT-
3′; NFATC1: 5′-AAAGACGCAGAAACGACG-3′ and 5′-TCTCACTAACGGGA
CATCAC-3′; PRDM1: 5′- TCTTGTGTGGTATTGTCGGGA-3′ and 5′-TGCTCG
GTTGCTTTAGACTGC-3′; CALCR: 5′- CTGAAGCTTGAGCGCCTGAGTC-3′
and 5′-TGGGGTTGGGTGATTTAGAAGAAG-3′; ITGB3: 5′- GGAAGAACGCG
CCAGAGCAAAATG-3′ and 5′-CCCCAAATCCCTCCCCACAAATAC-3′;
EIF2AK2: 5′-AATGCCGCAGCCAAATTAGC-3′ and 5′-AGGCCTATGTAATT
CCCCATGG-3′; IFNB1: 5′- AGAAGCTCCTGTGGCAATTG-3′ and 5′- ACTGCT
GCAGCTGCTTAATC-3′; GAPDH: 5′-ATCAAGAAGGTGGTGAAGCA-3′ and
5′- GTCGCTGTTGAAGTCAGAGGA-3′.
For quantiﬁcation of miRNA, total RNA was isolated, and the small RNA
fraction was enriched with the mirVana miRNA Isolation Kit (Thermo Fisher
Scientiﬁc) according to the manufacturer’s instructions. For quantitative RT-PCR
analysis of miRNA, cDNA was prepared from small RNAs with the TaqMan
miRNA Reverse Transcription Kit (Thermo Fisher Scientiﬁc). TaqMan miRNA
assays were used according to the manufacturer’s recommendations (Thermo
Fisher Scientiﬁc) for real-time PCR. The TaqMan U6 snRNA assay (Thermo Fisher
Scientiﬁc) was used for normalization of miRNA expression values.
Immunoblot analysis. Total cell extracts were obtained using lysis buffer con-
taining 150 mM Tris-HCl (pH 6.8), 6% SDS, 30% glycerol, and 0.03% Bromo-
phenol Blue; 10% 2-ME was added immediately before harvesting cells. Cell lysates
were fractionated on 7.5% SDS-PAGE, transferred to Immobilon-P membranes
(Millipore), and incubated with speciﬁc antibodies. Western Lightning plus-ECL
(PerkinElmer) was used for detection. NFATc1 antibody (556602, 1:1000) was
from BD Biosciences; Blimp1 (sc-47732, 1:1000), PKR (sc-6282, 1:1000), GAPDH
(sc-25778, 1:3000), and p38α (sc-535, 1:3000) antibodies were from Santa Cruz
Biotechnology. Densitometry was performed using ImageJ software (http://imagej.
nih.gov/ij/). The uncropped scans of the western blots are provided in the Sup-
plementary information.
RNA-seq and bioinformatics analysis. Total RNA was extracted using RNeasy
Mini Kit (QIAGEN) following the manufacturer’s instructions. True-seq RNA
Library preparation kits (Illumina) were used to purify poly-A+ transcripts and
generate libraries with multiplexed barcode adapters following the manufacturer’s
instructions. All samples passed quality control analysis using a Bioanalyzer 2100
(Agilent). RNA-seq libraries were constructed per the Illumina TrueSeq RNA
sample preparation kit. High-throughput sequencing was performed using the
Illumina HiSeq 4000 in the Weill Cornell Medical College Genomics Resources
Core Facility. RNA-seq reads were aligned to the mouse genome (mm10) using
TopHat65 or HISAT266. Cufﬂinks67 was subsequently used to assemble the aligned
reads into transcripts and then estimate the transcript abundances as RPKM (reads
per kilo base per million) values. HT-seq68 was used to calculate raw reads counts
and edgeR69 was used to calculate normalized counts as CPM (counts per million).
Mapped reads were at an average of 39 million per library. Heatmaps were gen-
erated by pheatmap package in R. Genes with false discovery rate (FDR) < 0.05
were identiﬁed as signiﬁcantly differentially expressed genes (DEG) between con-
ditions using the edgeR analysis of two RNA-seq biological replicates. To identify
miR-182 regulated pathways, we performed Gene Ontology (GO) analysis with
Panther Classiﬁcation System70 input with the RANKL-regulated DEG genes that
were more expressed in Mir182ΔM/ΔM cells than WT cells (≥1.5 fold). miR-182
regulated pathways by the GO analysis were ranked based on the p values. Gene Set
Enrichment Analysis (GSEA program, Broad Institute) input with the RANKL-
regulated DEG genes was performed according to the program’s instructions.
Hallmark pathways by GSEA were ranked based on the normalized enrichment
score (NES). p and FDR values were calculated following the program’s
instructions.
ELISA. Mouse serum IFN-β was measured by using VeriKine-HS Mouse Interferon
Beta Serum ELISA Kit (PBL Assay Science) according to the manufacturer’s
instruction.
Luciferase reporter assay. A 479 bp DNA fragment of the 3′ UTR of Eif2ak2
containing the miR-182 seed sequence was cloned into the pMIR-REPORT miRNA
Expression Reporter Vector (AM5795, ThermoFisher). The miR-182 seed sequence
was mutated using PrimeSTAR MAX DNA polymerase (Takara BIO) to generate a
mutant 3′UTR reporter plasmid with miss-matched miR-182 binding site. The 3′
UTR reporters were co-transfected to human embryonic kidney 293 cells with
CMV-renilla luciferase reporter (as an internal transfection control), together with
miR-182 mimic or a corresponding control using TransIT-TKO transfection
reagent (Mirus) in accordance with the manufacturer’s instructions. Forty-eight
hours after transfection, the cells were lysed with passive lysis buffer (Promega),
and ﬁreﬂy and renilla luciferase activities were measured using the dual-luciferase
reporter assay system (Promega).
Statistical analysis. Statistical analysis was performed using Graphpad Prism®
software. Two-tailed Student’s t test was applied when there were only two groups
of samples. In the case of more than two groups of samples, one-way ANOVA was
used with one condition, and two-way ANOVA was used with more than two
conditions. ANOVA analysis was followed by post hoc Bonferroni’s correction for
multiple comparisons. p < 0.05 was taken as statistically signiﬁcant; *p value < 0.05
and **p value < 0.01. The data displayed normal distribution. The estimated var-
iance was similar between experimental groups. Data are presented as the mean ±
SD or ± SEM as indicated in the ﬁgure legends.
Data availability
Data supporting the ﬁndings of this manuscript are available from the corresponding
author upon reasonable request. RNA-seq data (accession #GSE108721) have been
deposited in NCBI’s Gene Expression Omnibus (http://www.ncbi.nlm.nih.gov/geo/
query/acc.cgi?acc=GSE108721).
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